海南海药股份有限公司关于日常关联交易的公告

Core Viewpoint - The announcement details the daily related transactions between Hainan Haiyao Co., Ltd. and its affiliate Chongqing Jinsai Pharmaceutical Co., Ltd., with expected transaction amounts for 2026 not exceeding 16 million yuan, following a cash-before-delivery model [1][3]. Group 1: Daily Related Transactions Overview - Hainan Haiyao's board approved the related transactions on December 30, 2025, with revenue from these transactions amounting to 2.81 million yuan in 2025 [1]. - The expected transaction amount for 2026 is capped at 16 million yuan, with payments made in full before delivery [1][3]. Group 2: Affiliate Information - Chongqing Jinsai Pharmaceutical Co., Ltd. is identified as an affiliate, previously holding over 5% of shares in Hainan Haiyao, and is influenced by Liu Xicheng, the actual controller of Shenzhen Nanfang Tongzheng Investment Co., Ltd. [2][3]. Group 3: Transaction Terms and Conditions - The transactions are based on normal commercial practices, adhering to principles of equality, mutual benefit, and fairness, with prices determined through market references [3][7]. - Payment arrangements and settlement methods are executed according to contractual agreements [5][6]. Group 4: Impact on the Company - The related transactions are deemed normal business activities that do not harm the interests of the company or its shareholders, particularly minority shareholders [7][8]. - The company maintains independence from the affiliate in various aspects, ensuring no adverse effects on its financial status or operational results [7][8]. Group 5: Independent Directors' Opinions - Independent directors have reviewed and approved the related transactions, affirming their alignment with the company's business needs and compliance with legal regulations [8].